Patents by Inventor Nicholas D. Smith

Nicholas D. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of an androgen receptor modulator
    Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10526310
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 7, 2020
    Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Crystalline Forms Of An Androgen Receptor Modulator
    Publication number: 20190330182
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Farnesoid X receptor agonists and uses thereof
    Patent number: 10377717
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 13, 2019
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek
  • Crystalline Forms Of An Androgen Receptor Modulator
    Publication number: 20190241539
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10308630
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Estrogen receptor modulators and uses thereof
    Patent number: 10227334
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20190062277
    Abstract: Described herein are compounds that are famesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with famesoid X receptor activity.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 28, 2019
    Inventors: Nicholas D. SMITH, Steven P. GOVEK, Karensa L. Douglas
  • FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20180282263
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Application
    Filed: September 16, 2016
    Publication date: October 4, 2018
    Inventors: Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
  • Crystalline Forms Of An Androgen Receptor Modulator
    Publication number: 20180258067
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Anna DILHAS, Mark R. HERBERT, Ouathek OUERFELLI, Nicholas D. Smith
  • FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20180251429
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Inventors: Nicholas D. SMITH, Steven P. GOVEK
  • FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20180244606
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 30, 2018
    Inventors: Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
  • Heterocyclic estrogen receptor modulators and uses thereof
    Patent number: 10053451
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 21, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
  • Androgen receptor modulators and uses thereof
    Patent number: 10023556
    Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: July 17, 2018
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Nicholas D. Smith, Celine Bonnefous, Jackaline D. Julien
  • Crystalline forms of an androgen receptor modulator
    Patent number: 9994545
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 12, 2018
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Estrogen receptor modulators and uses thereof
    Patent number: 9873684
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Estrogen receptor modulators and uses thereof
    Patent number: 9868704
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 16, 2018
    Assignee: Genentech, Inc.
    Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Mark R. Herbert, Karensa L. Douglas
  • Methods and compositions for modulating estrogen receptor mutants
    Patent number: 9855270
    Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. Roychowdhury, Lori Friedman, Deepak Sampath
  • Estrogen receptor modulators and uses thereof
    Patent number: 9845291
    Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith, Simon Charles Goodacre, Nicholas Charles Ray
  • Crystalline forms of an estrogen receptor modulator
    Patent number: 9783503
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl) phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 10, 2017
    Assignee: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Mark R. Herbert